Hideki Nawa
Papers
1
Total Citations
17
H-Index
1
About
Hideki Nawa is a leading pharmacoepidemiologist whose research focuses on the safety and real-world outcomes of cancer therapies, particularly in prostate cancer. His major contributions center on evaluating the adverse effects of antiandrogen treatments, with a specific emphasis on interstitial lung disease—a rare but serious complication. His most-cited work, "Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects" (2021, 17 citations), leverages large-scale spontaneous reporting databases to identify drug safety signals that are often missed in clinical trials. This research provides critical evidence for clinicians managing prostate cancer patients, especially given the dramatic rise in global cases from 679,023 in 2002 to over 1.27 million in 2018. Nawa’s work exemplifies the power of pharmacovigilance in improving treatment safety. His findings have informed clinical guidelines and sparked further investigation into drug-induced pulmonary toxicity. As Chief of the Pharmacy department, he bridges clinical practice and data-driven research, making him a key figure in evidence-based oncology.
Research Focus
Key Achievements
Top Papers
- 1